Drug intelligence / Profile preview

technetium(99mTc) N-pyridoxyl-5-methyltryptophan

Development stage: Unknown
Lead developer: Nihon Medi-Physics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Technetium(99mTc) N-pyridoxyl-5-methyltryptophan is a **radiopharmaceutical** used in hepatobiliary scintigraphy as a diagnostic imaging agent for liver and biliary tract diseases. It acts as an effective radiotracer among (99mTc)-pyridoxylaminates, allowing noninvasive visualization and quantification of hepatobiliary transporter function through emission of gamma radiation detected by SPECT imaging. Its hepatic uptake is mediated by organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3, while its biliary excretion involves multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2). The compound is not metabolized in the human liver and enables assessment of drug pharmacokinetics and liver/biliary health. Developed and marketed in Japan since 1984.

Brand names: Hepatimage
Other names: Technetium(99mTc) N-pyridoxyl-5-methyltryptophan放射性医薬品基準Ｎ-ピリドキシル-5-メチルトリプトファンテクネチウム(99mTc)注射液

Targets

OATP1B1 (Organic anion transporting polypeptide 1B1)MRP2 (Canalicular multispecific organic anion transporter 1)SLCO1B3 (Organic anion transporting polypeptide 1B3)

Beyond the preview

Go deeper on technetium(99mTc) N-pyridoxyl-5-methyltryptophan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium(99mTc) N-pyridoxyl-5-methyltryptophan.

Explore the full profile